{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T18:23:23Z","timestamp":1771871003870,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T00:00:00Z","timestamp":1694390400000},"content-version":"vor","delay-in-days":1989,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","jpain.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pain"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.jpain.2017.11.007","type":"journal-article","created":{"date-parts":[[2017,12,8]],"date-time":"2017-12-08T17:18:10Z","timestamp":1512753490000},"page":"439-453","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Assessment of Tapentadol API Abuse Liability With the Researched Abuse, Diversion and Addiction-Related Surveillance System"],"prefix":"10.1016","volume":"19","author":[{"given":"Suzanne K.","family":"Vosburg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Geoffrey","family":"Severtson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard C.","family":"Dart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodore J.","family":"Cicero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven P.","family":"Kurtz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark W.","family":"Parrino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jody L.","family":"Green","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpain.2017.11.007_bib0010","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1477-7517-8-29","article-title":"Abuse risks and routes of administration of different prescription opioid compounds and formulations","volume":"8","author":"Butler","year":"2011","journal-title":"Harm Reduct J"},{"key":"10.1016\/j.jpain.2017.11.007_bib0015","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jpain.2012.08.008","article-title":"Abuse rates and routes of administration of reformulated extended-release oxycodone: Initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment","volume":"14","author":"Butler","year":"2013","journal-title":"J Pain"},{"key":"10.1016\/j.jpain.2017.11.007_bib0020","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/pme.12524","article-title":"Tapentadol abuse potential: A postmarketing evaluation using a sample of individuals evaluated for substance abuse treatment","volume":"16","author":"Butler","year":"2015","journal-title":"Pain Med"},{"key":"10.1016\/j.jpain.2017.11.007_bib0025","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/AJP.0000000000000067","article-title":"Comparison of the risks of shopping behavior and opioid abuse between tapentadol and oxycodone and association of shopping behavior and opioid abuse","volume":"30","author":"Cepeda","year":"2014","journal-title":"Clin J Pain"},{"key":"10.1016\/j.jpain.2017.11.007_bib0030","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.jpain.2013.05.010","article-title":"Comparison of the risks of opioid abuse or dependence between tapentadol and oxycodone: results from a cohort study","volume":"14","author":"Cepeda","year":"2013","journal-title":"J Pain"},{"key":"10.1016\/j.jpain.2017.11.007_bib0035","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jpain.2012.10.012","article-title":"Comparison of opioid doctor shopping for tapentadol and oxycodone: a cohort study","volume":"14","author":"Cepeda","year":"2013","journal-title":"J Pain"},{"key":"10.1016\/j.jpain.2017.11.007_bib0040","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/AJP.0b013e3182201983","article-title":"Effect of tapentadol extended release on productivity: results from an analysis combining evidence from multiple sources","volume":"28","author":"Cepeda","year":"2012","journal-title":"Clin J Pain"},{"key":"10.1016\/j.jpain.2017.11.007_bib0045","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1001\/jamapsychiatry.2014.3043","article-title":"Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States: Lessons learned from OxyContin","volume":"72","author":"Cicero","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jpain.2017.11.007_bib0050","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/pds.1113","article-title":"Rates of abuse of tramadol remain unchanged with the introduction of new branded and generic products: Results of an abuse monitoring system, 1994\u20132004","volume":"14","author":"Cicero","year":"2005","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jpain.2017.11.007_bib0055","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/AJP.0000000000000001","article-title":"Nonmedical use of tapentadol immediate release by college students","volume":"30","author":"Dart","year":"2014","journal-title":"Clin J Pain"},{"key":"10.1016\/j.jpain.2017.11.007_bib0060","doi-asserted-by":"crossref","first-page":"395","DOI":"10.5055\/jom.2012.0139","article-title":"Assessment of the abuse of tapentadol immediate release: The first 24 months","volume":"8","author":"Dart","year":"2012","journal-title":"J Opioid Manag"},{"key":"10.1016\/j.jpain.2017.11.007_bib0065","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMsa1406143","article-title":"Trends in opioid analgesic abuse and mortality in the United States","volume":"372","author":"Dart","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpain.2017.11.007_bib0070","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1093\/pm\/pnv032","article-title":"Diversion and Illicit sale of extended release tapentadol in the United States","volume":"17","author":"Dart","year":"2016","journal-title":"Pain Med"},{"key":"10.1016\/j.jpain.2017.11.007_bib0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0041181","article-title":"Using poison center exposure calls to predict methadone poisoning deaths","volume":"7","author":"Dasgupta","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jpain.2017.11.007_bib0080","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.2196\/jmir.2810","article-title":"Crowdsourcing black market prices for prescription opioids","volume":"15","author":"Dasgupta","year":"2013","journal-title":"J Med Internet Res"},{"key":"10.1016\/j.jpain.2017.11.007_bib0085","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/pds.3533","article-title":"Using poison center exposure calls to predict prescription opioid abuse and misuse-related emergency department visits","volume":"23","author":"Davis","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jpain.2017.11.007_bib0090","doi-asserted-by":"crossref","first-page":"149","DOI":"10.5055\/jom.2014.0203","article-title":"Evaluation of the tamper-resistant properties of tapentadol extended-release tablets: Results of in vitro laboratory analyses","volume":"10","author":"Galia","year":"2014","journal-title":"J Opioid Manag"},{"key":"10.1016\/j.jpain.2017.11.007_bib0095","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.phrs.2014.09.006","article-title":"Hydrocodone extended-release: pharmacodynamics, pharmacokinetics and behavioral pharmacology of a controversy","volume":"91","author":"Gould","year":"2015","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jpain.2017.11.007_bib0100","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/pds.3723","article-title":"Impact of abuse-deterrent OxyContin on prescription opioid utilization","volume":"24","author":"Hwang","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jpain.2017.11.007_bib0105","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1080\/10550880903182986","article-title":"The \u201cblack box\u201d of prescription drug diversion","volume":"28","author":"Inciardi","year":"2009","journal-title":"J Addict Dis"},{"key":"10.1016\/j.jpain.2017.11.007_bib0110","first-page":"127","article-title":"The diversion of prescription opioid analgesics","volume":"7","author":"Inciardi","year":"2007","journal-title":"Law Enforc Exec Forum"},{"key":"10.1016\/j.jpain.2017.11.007_bib0115","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/pds.2090","article-title":"Characterization of acetaminophen overdose-related emergency department visits and hospitalizations in the United States","volume":"20","author":"Manthripragada","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jpain.2017.11.007_bib0120","first-page":"1","article-title":"Comparing prescription opioids, methadone, and heroin endorsement rates from the treatment episode data set to the RADARS system treatment center programs","volume":"Q3","author":"McDaniel","year":"2016","journal-title":"Radars Syst Tech Rep"},{"key":"10.1016\/j.jpain.2017.11.007_bib0125","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/pme.12547","article-title":"Assessing abuse potential of new analgesic medications following market release: An evaluation of Internet discussion of tapentadol abuse","volume":"16","author":"McNaughton","year":"2015","journal-title":"Pain Med"},{"key":"10.1016\/j.jpain.2017.11.007_bib9010","doi-asserted-by":"crossref","first-page":"962","DOI":"10.3109\/15563650.2015.1102927","article-title":"2014 annual report of the american association of poison control centers' national poison data system (NPDS): 32nd annual report","volume":"53","author":"Mowry","year":"2015","journal-title":"Clin Toxicol"},{"key":"10.1016\/j.jpain.2017.11.007_bib0130","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1517\/14656566.2012.696097","article-title":"Mechanistic and functional differentiation of tapentadol and tramadol","volume":"13","author":"Raffa","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jpain.2017.11.007_bib0135","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.drugalcdep.2016.09.018","article-title":"Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone","volume":"168","author":"Severtson","year":"2016","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.jpain.2017.11.007_bib0140","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/00952990600753982","article-title":"Clinician validation of Poison Control Center (PCC) intentional exposure cases involving prescription opioids","volume":"32","author":"Smith","year":"2006","journal-title":"Am J Drug Alcohol Abuse"},{"key":"10.1016\/j.jpain.2017.11.007_bib0145","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00213-013-3031-y","article-title":"Miotic and subject-rated effects of therapeutic doses of tapentadol, tramadol, and hydromorphone in occasional opioid users","volume":"228","author":"Stoops","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.jpain.2017.11.007_bib0150","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s40263-014-0151-9","article-title":"The mu-opioid receptor agonist\/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: The case of tapentadol","volume":"28","author":"Tzschentke","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jpain.2017.11.007_bib0155","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1358\/dot.2009.45.7.1395291","article-title":"Tapentadol hydrochloride: A next-generation, centrally acting analgesic with two mechanisms of action in a single molecule","volume":"45","author":"Tzschentke","year":"2009","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.jpain.2017.11.007_bib0160","series-title":"National Forensic Laboratory Information System Special Report: Opiates and Related Drugs Reported in NFLIS 2009\u20132014","author":"United States Drug Enforcement Administration, Office of Diversion Control","year":"2015"},{"key":"10.1016\/j.jpain.2017.11.007_bib0165","series-title":"National Forensic Laboratory Information System: Midyear Report 2015","author":"United States Drug Enforcement Administration, Office of Diversion Control","year":"2016"},{"key":"10.1016\/j.jpain.2017.11.007_bib0170","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/add.12114","article-title":"A comparison among tapentadol tamper-resistant formulations (TRF) and OxyContin(R) (non-TRF) in prescription opioid abusers","volume":"108","author":"Vosburg","year":"2013","journal-title":"Addiction"},{"key":"10.1016\/j.jpain.2017.11.007_bib0175","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jpain.2016.02.015","article-title":"Analysis of the abuse and diversion of the buprenorphine transdermal delivery system","volume":"17","author":"Wiegand","year":"2016","journal-title":"J Pain"},{"key":"10.1016\/j.jpain.2017.11.007_bib0180","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1056\/NEJMp0908913","article-title":"A difficult balance\u2013pain management, drug safety, and the FDA","volume":"361","author":"Woodcock","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpain.2017.11.007_bib0185","series-title":"Tramadol Update Review Report","author":"World Health Organization Expert Committee on Drug Dependence","year":"2014"}],"container-title":["The Journal of Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526590017307848?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526590017307848?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T23:58:28Z","timestamp":1694908708000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526590017307848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S1526590017307848"],"URL":"https:\/\/doi.org\/10.1016\/j.jpain.2017.11.007","relation":{},"ISSN":["1526-5900"],"issn-type":[{"value":"1526-5900","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of Tapentadol API Abuse Liability With the Researched Abuse, Diversion and Addiction-Related Surveillance System","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pain","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpain.2017.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 Published by Elsevier Inc. on behalf of the American Pain Society","name":"copyright","label":"Copyright"}]}}